All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for SANOFI, U.S. · Global life sciences company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 4

JEANNE HAGGERTY

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
KURT SCHRADER Former member of Congress

Previously held: Former Member of Congress
CHRISTOPHER E. WILCOX

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
ROBERT BUTORA New on this filing

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Budget/Appropriations

Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.

Medicare/Medicaid

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Medical/Disease Research/Clinical Labs

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.

Health Issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

Taxation/Internal Revenue Code

Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.